TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$100 Million

Urogen Pharma, Ltd.

Sole Placement Agent and Exclusive Financial Advisor, March 2022

Urogen Pharma, Ltd.
Senior Secured Term Loan

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means.

More Like This

Mar 2024

Exchange of all Outstanding Series B Convertible Preferred Stock for Common Stock

Financial Advisor

View Details >
Mar 2024
$600 Million

Follow-on Offering

Bookrunner

View Details >
Mar 2024
$150 Million

Underwritten Offering

Lead Left Bookrunner

View Details >